Alterations of the Cell-Cycle Inhibitors p27KIP1 and p16INK4a Are Frequent in Blastic Plasmacytoid Dendritic Cell Neoplasms  by Wiesner, Thomas et al.
Alterations of the Cell-Cycle Inhibitors p27KIP1
and p16INK4a Are Frequent in Blastic Plasmacytoid
Dendritic Cell Neoplasms
Thomas Wiesner1,4, Anna C. Obenauf2,4, Carlo Cota3, Isabella Fried1, Michael R. Speicher2 and Lorenzo
Cerroni1
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive malignancy with a median
survival of 12–14 months. To identify pathogenetic relevant genomic aberrations and molecular targets for
therapy, we analyzed skin biopsy samples obtained from 14 patients using high-resolution array-based
comparative genomic hybridization and immunostaining. Losses of chromosomes 9, 12, 13, and 15 were
detected most frequently. Loss of the CDKN1B locus was the most common finding and was detected in 64% of
tumors. In all but one case, the dose-dependent haploinsufficient cell-cycle inhibitor p27KIP1, encoded by
CDKN1B, was weakly expressed in the nuclei of tumor cells. Losses of the CDKN2A–ARF–CDKN2B locus
occurred in 50% of patients, and in one case a distinct biallelic loss was identified. The cell-cycle inhibitor
p16INK4a, which is encoded by CDKN2A, was not expressed in tumor cells, suggesting a complete loss of
function. Loss of chromosome 13, including the RB1 gene, was observed in 43% of tumors. These results imply
that alterations of the cell-cycle checkpoint controlling proteins p27KIP1, p16INK4a, and RB1 may exert a profound
effect in malignant transformation in BPDCN. The elucidation of the affected pathways may guide the
development of new treatments specifically designed for this aggressive disease entity.
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INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a
rare malignant proliferation derived from precursors of
plasmacytoid dendritic cells. Clinically, patients usually
present with reddish-brown (‘‘bruise-like’’), asymptomatic
skin plaques and tumors, often followed by bone marrow,
lymph node, and blood involvement. Although most cases
show an initial response to multiagent chemotherapy, relapses
are frequent and the clinical course is aggressive with a
median survival of 12–14 months (Facchetti et al., 2008).
Genetic aberrations have only been studied in a limited
number of cases. Using techniques such as karyotyping,
fluorescence in situ hybridization, or low-resolution com-
parative genomic hybridization (CGH), chromosomal ab-
normalities have been detected in 70% of cases. In these
studies, alterations of chromosome regions 5q, 6q, 9, 12p,
13q, and 15q were most commonly found (Petrella et al.,
1999; Leroux et al., 2002; Mao et al., 2003; Reichard et al.,
2005). A combined array-CGH and gene-expression study of
five cases showed recurrent deletions of chromosomal
regions 4q34, 9, and 13q12–q31. In this study, the RNA
expression of the tumor suppressor genes RB1 and LATS2 was
decreased, whereas the expression of oncogenes HES6,
RUNX2, and FLT3 was increased (Dijkman et al., 2007).
Recently, an array-CGH study analyzed nine blood or lymph
node samples of BPDCN and reported deletions of the tumor
suppressor genes RB1, CDKN1B, CDKN2A, and TP53 (Jardin
et al., 2009). The authors suggested that the loss of these
genes may represent crucial oncogenetic events in BPDCN,
because they may alter the G1/S transition.
Although studies by Dijkman et al. and Jardin et al. nicely
demonstrated the power of array CGH to characterize genomic
alterations in BPDCN, genetic data for this disease still remain
limited and variable. In this study, we significantly extend the
genetic data of BPDCN in a series of 14 patients and confirm
the central genetic results on the protein level. Owing to the
aggressive clinical course and the currently insufficient
treatment options, we discuss possible implications of the
revealed alterations for new therapeutic strategies.
RESULTS AND DISCUSSION
Patients and recurrent genomic changes
All 14 patients presented with typical clinical and histological
features (1 woman, 13 men; aged 38–89 years; mean age
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68 years; Table 1). Only pretreatment skin biopsy samples
were analyzed using genome-wide, high-resolution array
CGH. Chromosomal aberrations, predominantly losses, were
observed in all analyzed samples. Losses on chromosomes 12
(8 cases), 9 (7 cases), 13 (6 cases), and 15 (5 cases) were
detected most frequently (Figure 1, Table 2). Analysis of
available follow-up data did not show any correlation
between specific sets of genetic aberrations or p27KIP1 and
p16INK4a immunohistochemical staining patterns and prog-
nosis (Table 1). A complete summary of genomic aberrations
of each case, including ideograms, start and stop positions of
deleted/duplicated regions, and affected genes is included in
Supplementary Table S1.
Loss of chromosome region 12p13 and the weak expression
of p27KIP1
Loss of the chromosome region 12p13 was the most frequent
finding (Figure 2a). The common deleted region had a size of
only 1.6Mb and includes the CDKN1B gene, which encodes
the p27KIP1 protein. To further confirm the involvement of this
gene in oncogenesis, we performed immunostaining and
found in all but 1 of our 14 cases, a weak expression of
p27KIP1 in the nuclei of tumor cells (Figure 2c). Between these
weakly p27KIP1-expressing cells, few scattered tumor cells
with a strong nuclear expression were constantly found. The
monoallelic losses of CDKN1B in 64% of cases and the weak
nuclear expression of p27KIP1 in the great majority of tumor
cells indicate the presence of an unaltered second allele.
The p27KIP1 protein is an important dose-dependent
haploinsufficient tumor suppressor and has complex func-
tions in cell-cycle regulation (Chu et al., 2008). High levels of
p27KIP1 arrest the cell cycle by inhibiting cyclin E-dependent
kinases, but low levels of p27KIP1 drive the cell cycle by
stabilizing cyclin D-dependent kinases (Sherr and Roberts,
2004). Inactivation of both p27KIP1 alleles is rare in tumors,
possibly because it may not provide sufficient advantage over
the heterozygous state (Fero et al., 1998). In most human
malignancies, including lung, breast, ovarial, prostatic,
gastric, and colon cancer, deletions and mutations of
CDKN1B are rare, but downregulation of p27KIP1 due to
other mechanisms is common and correlates strongly with
high tumor grade and poor prognosis (Chu et al., 2008). The
frequent loss of the CDKN1B gene in BPDCN, and the
constantly weak expression of its gene product p27KIP1, may
indicate a profound effect on tumorigenesis, and may partly
explain the aggressiveness of this disease.
The commonly deleted 12p13 region also harbors the
ETV6 gene, which acts as a transcriptional repressor. In
hematological malignancies, alterations of both ETV6 alleles
are frequently observed; one allele is involved in a
translocation resulting in the formation of a new fusion gene,
whereas the second allele is lost (Bohlander, 2005). These
concomitant translocations and deletions led to the sugges-
tion that ETV6 may act as a tumor suppressor, but the
oncogenetic relevance seems to result more from the
formation of fusion genes than from deletions (Bohlander,
2005). However, translocations involving ETV6 have not yet
been reported by karyotyping of BPDCN (Petrella et al.,
1999; Leroux et al., 2002; Reichard et al., 2005), and the
relevance of the ETV6 loss alone is at present unclear.
Loss of chromosome 9 and no expression of p16INK4a
Chromosome 9 was the second most commonly affected in
our series. Interestingly, in one case, we found a small
biallelic deletion of only 500 kb (Figure 2b), harboring the
CDKN2A–ARF–CDKN2B locus, which encodes the two
inhibitors of cyclin D-dependent kinases, p15INK4b and
p16INK4a, and the unrelated ARF protein. In all of our cases,
Table 1. Clinical and immunohistological features of our patients
Case Age, years Sex Skin lesions at diagnosis Extracutaneous disease at presentation Follow-up, months p27 p16
1 65 M Generalized No A++, 6 ± 
2 73 M Generalized Yes A++, 12 ± 
3 74 M Localized No A+, 26 ± 
4 58 F Localized No A++, 22 ± 
5 76 M Generalized No NA ± 
6 89 M Generalized Yes DoD, 2  1
7 77 M Generalized No NA ± 
8 84 M Generalized Yes DoD, 9 ± 
9 50 M Generalized Yes NA ± 
10 38 M Localized No CR, 12 ± 
11 42 M Generalized NA DoD, 1 ± 
12 87 M Localized No NA ± 
13 80 M Generalized No DoD, 2 ± 
14 57 M Generalized No A+, 3 ± 
Abbreviations: A+ alive with skin disease; A++ alive with skin and systemic disease; CR, complete remission; DoD, died of disease; F, female; M, male; NA,
not available; ±, predominant weak nuclear staining with scattered cells with stronger signal.
1Scattered positive; , negative.
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immunostaining showed that p16INK4a was indeed not
expressed in tumor cells (Figure 2d). The losses of the
CDKN2A–ARF–CDKN2B locus in 50% of our patients, and
the biallelic loss in one of them, as well as the constantly
negative expression of p16INK4a is highly suggestive of a
complete loss of function of p16INK4a. In addition to the
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Figure 1. Genomic aberrations in BPDCN detected by array CGH. (a) The ideogram summarizes chromosomal gains and losses of 14 patients. The
green and red bars on the right side of each chromosome indicate how often, that is, in what percentage, copy number changes were found. Losses are
displayed in green in the left half of each figure, and gains are shown in red in the right half. Deletions at chromosomes 9, 12, 13, 15, and 19 were most often
observed, whereas other changes only occurred in a low percentage of cases. (b) Representative genome-wide array-CGH profile of case 1. On the x axis,
the data are organized along the 22 autosomal chromosomes and the 2 sex chromosomes. The y axis shows the relative copy number on a logarithmic scale.
The blue bars define losses on chromosome 1, 6, 9, 12, 13. Abbreviations: BPDCN, blastic plasmacytoid dendritic cell neoplasm; CGH, comparative genomic
hybridization.
1154 Journal of Investigative Dermatology (2010), Volume 130
T Wiesner et al.
p27KIP1 and p16INK4a in BPDCN
observed losses of the CDKN2A–ARF–CDKN2B locus, other
mechanisms such as mutations or epigenetic modifications
may affect the undeleted p16INK4a alleles.
Gene products of the CDKN2A–ARF–CDKN2B locus fulfill
the classical Knudson criteria for tumor suppression (‘‘2-hit’’
model) and participate in major tumor suppressor networks
that are disabled in human cancer. The p16INK4a and
p15INK4b proteins both arrest the cell cycle by inhibiting the
cyclin D-dependent-kinases-mediated phosphorylation of
RB1 (Kim and Sharpless, 2006). ARF inhibits the degradation
of the p53 protein (Kim and Sharpless, 2006). Losses of these
proteins in BPDCN harmfully deregulate both the RB1 and
p53 pathways, indicating a critical involvement in the
pathogenesis of this tumor entity.
Although losses of the CDKN2A–ARF–CDKN2B locus
were also reported by Jardin et al., we additionally found
frequent losses (X50%) in chromosomal regions 9p21.1,
9p13.3, and 9q34.2. This suggests that other regions and their
respective genes on chromosome 9 may be involved in
BPDCN pathogenesis.
Losses of chromosome 13 and RB1
We observed chromosome 13 deletions in 43% of tumors,
which involved large parts of the chromosome and several
tumor suppressor genes. Among those, the RB1 gene is most
prominent and arrests the cell cycle by repressing the
transcription of genes, the products of which are required
for DNA synthesis. Cyclin D-dependent kinases, which are
possibly hyperactive because of losses of their inhibitors
p16INK4a and p15INK4b, phosphorylate RB1 and cancel its
growth-inhibitory effects. Jardin et al. (2009) suggested that
RB1might be the target gene in this region, and Dijkman et al.
(2007) demonstrated a diminished gene expression of RB1
using RNA microarray analyses of five BPDCNs. A profound
effect of RB1 on tumorigenesis of BPDCN seems likely.
Losses on chromosomes 5q, 9, 12, 13, and 15 are most common
Our results significantly extend the current knowledge
regarding genetic changes in BPDCN. The three largest
previous studies altogether comprised data on 27 patients
(Leroux et al., 2002; Dijkman et al., 2007; Jardin et al., 2009).
Together with the 14 new cases described in this study, a
relatively homogeneous pattern of common alterations in this
tumor entity emerges. Losses of the common deleted region
on chromosomes 9, 12, and 15 were detected in our patients
and in the 3 studies in B50, 60, and 30% of cases,
respectively. Losses of chromosome 13 and 5q were found
in our patients in a lower percentage than in the pooled data
set (43 vs 73% and 21 vs 48%, respectively). Other genomic
aberrations such as losses at 6q (Leroux et al., 2002), 4q
(Dijkman et al., 2007), or 17p (Jardin et al., 2009), were
found inconsistently in the three studies, and were also
uncommon in our patients.
Conclusions and possible therapeutic implications
Our data are in agreement with previous notions by Jardin
et al. that the most frequently observed deletions in the
BPDCN tumor genomes most likely affect the G1/S transition.
The alteration of the important cell-cycle regulating genes,
namely CDKN1B, CDKN2A, ARF, CDKN2B, and RB1, may
contribute to overactive cell-cycle kinases, which is often
associated with aberrant division and uncontrolled prolifera-
tion of cancer cells.
The elucidation of the affected pathways in this disease
may guide the development of new treatment options,
specifically designed for this tumor entity. For example, in
this study, we demonstrate the downregulation of p27KIP1,
which likely destabilizes cell-cycle control. Restoration of
normal p27KIP1 levels may represent an efficient treatment
option and could possibly be achieved by treatment with the
mammalian target of rapamycin inhibitors (Chu et al., 2008;
Meric-Bernstam and Gonzalez-Angulo, 2009). Inhibitors of
mammalian target of rapamycin induce cell-cycle arrests in
various cell systems by inactivating cyclin D-dependent
kinases, which are believed to result from the downregulation
of D-type cyclins and accumulation of p27KIP1. Moreover, the
downregulation of D-type cyclins may also reduce the
negative impact of p16INK4a and p15INK4b losses on the cell
cycle. Clinical trials using mammalian target of rapamycin
inhibitors have already shown promising results and clinical
benefits in several cancer types, including lymphoma. On the
basis of the genetic and immunostaining results, it seems
possible that mammalian target of rapamycin inhibitors may
be effective in BPDCN, and it seems worth evaluating their
efficacy in preclinical and clinical settings.
MATERIALS AND METHODS
Tumor samples and immunophenotyping
The study was approved by the institutional ethics committee and
was conducted according to the Declaration of Helsinki. The tumor
Table 2. Copy number changes and candidate genes
detected in more than 20% of cases
Chromosome
region
Affected
patients, % Change Candidate genes
12p13.2 64 Loss CDKN1B, ETV6
9p21.3, 9q34 50 Loss CDKN2A, CDKN2B, ARF1
13q12.11–q34 43 Loss RB1
15q11.2–q26.3 36 Loss 2
19p13.3–p13.4 29 Loss 2
3p22.2–p21.1 29 Loss PTPN23
5q32–q35.2 21 Loss 2
6q23.3–q27 21 Loss PARK2
7p22.3–p22.1 21 Loss MAD1L1
21q22.3 21 Loss 2
Abbreviation: BPDCN, blastic plasmacytoid dendritic cell neoplasm.
1In addition to the CDKN2A–ARF–CDKN2B locus, losses on chromosome
9 included large parts of the chromosome and several additional
candidate genes possible involved in the pathogenesis of BPDCN.
2Candidate genes are not mentioned, because losses included large
parts of chromosomes and hundreds of genes. For all cases, a list of
genomic aberrations including start and stop position, cytogenetic bands,
and fluorescence log2 ratio are included in Supplementary Table S1.
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samples were formalin-fixed, paraffin-embedded tissue archival
specimens (12 cases) or flash-frozen tissues (2 cases). The diagnosis
of BPDCN was made by two independent dermatopathologists with
appropriate immunohistochemical stainings as described previously
(Ascani et al., 2008; Facchetti et al., 2008). The protein expression of
p27KIP1 and p16INK4a was evaluated with a standard immunoperox-
idase technique using appropriate antibodies (p27KIP1: Dako,
Glostrup, Denmark; p16INK4a: MTM, Heidelberg, Germany).
DNA extraction
For DNA extraction, 10-mm sections were cut, and only areas with a
tumor cell infiltration of more than 90% were microdissected as
determined by a microscopic examination of adjacent sections.
DNA was purified using a QIAamp DNA FFPE Tissue Kit (Qiagen,
Hilden, Germany).
Array CGH
Samples were labeled using a Bioprime Array CGH Genomic
Labeling Kit according to the manufacturer’s instructions (Invitrogen,
Carlsberg, CA). Briefly, 500 ng test DNA and reference DNA
(Promega, Madison, WI) were differentially labeled with dCTP-Cy5
and dCTP-Cy3, respectively (GE Healthcare, Piscataway, NJ).
Genome-wide analysis of DNA copy number changes was conduc-
ted using an oligonucleotide array containing 44,000 probes with a
spatial resolution of 35 kb according to the manufacturer’s protocol
version 6.0 (Agilent, Santa Clara, CA). Slides were scanned using
Agilent’s microarray scanner G2505B and analyzed using Agilent
DNA Analytics software 4.0.76 (statistical algorithm: ADM-2;
sensitivity threshold: 8.0; consecutive clone filter: 10).
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Figure 2. Losses of chromosomes 9 and 12 in detail. (a) The common deleted region on chromosome 12, detected in 64% of cases, is only 1.6Mb large, and
contains the CDKN1B gene. The right part of this figure shows the array-CGH profile of case 1. The blue line follows a log ratio of 0 over large parts of
chromosome 12, indicating a normal copy number, but becomes negative at 12p13 (log ratio of 1), pointing at a monoallelic loss of this region. The shaded
blue area defines the lost region. (b) Losses on chromosome 9 were detected in 50% of cases. The right part of this figure illustrates a biallelic, 500 kb
sized deletion at 9p21.3 (case 8). The blue line shows the log ratio and indicates at 1, a monoallelic loss of the whole chromosome 9; valueso2 indicate an
additional loss of the CDKN2A–ARF–CDKN2B locus of the second chromosome. (c) Immunostaining of case 8 shows a weak expression of p27KIP1 in the nuclei
of tumor cells, but also scattered admixed malignant cells with a strong nuclear p27KIP1 expression. Bar¼ 10 mm. (d) Immunostaining for p16INK4a was constantly
negative as shown herein in case 7. Bar¼10 mm. Abbreviation: CGH, comparative genomic hybridization.
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